KORU Medical Systems, Inc. 10-Q — AI Bull & Bear Analysis

The Q1 2026 filing presents a company at a crossroads between successful commercial scaling and persistent operational inefficiency. KORU's ability to grow its international footprint and penetrate the pharma services market is a powerful signal of product-market fit for the FREEDOM System. The narrowing of net losses suggests that the company is beginning to find a path toward operating leverage, provided it can stabilize its cost structure. However, the trade-off for this growth is a tightening of the balance sheet and a decline in gross margins. The recent credit facility amendment provides a necessary safety net, but the new liquidity covenants place a premium on the company's ability to achieve positive EBITDA quickly. Investors must weigh the impressive 22% revenue growth against the risks of leadership transition and the volatility of clinical trial-based revenue streams to determine if the scaling narrative is sustainable.